High-risk hepatocellular carcinoma (HCC) research hub

A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

This clinical trial looks at whether giving two cancer medicines after liver cancer surgery or heat treatment helps stop the cancer returning. Researchers are comparing this combination of medicines against standard regular hospital check-ups in adults who have a higher chance of their liver cancer coming back.